Page last updated: 2024-09-05

sorafenib and stx-0119

sorafenib has been researched along with stx-0119 in 1 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (stx-0119)	Trials (stx-0119)	Recent Studies (post-2010) (stx-0119)
6,520	730	5,251	22	0	20

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Asai, A; Asakawa, N; Hirata, G; Kurita, A; Nishisaka, F; Ogo, N; Shishido, Y; Takagi, A; Takahashi, H; Taniguchi, K; Tsugane, M	1

Other Studies

1 other study(ies) available for sorafenib and stx-0119

Article	Year
Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701. Cancer science, 2020, Volume: 111, Issue:5 Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Interleukin-6; Mice; Molecular Docking Simulation; Mouth Neoplasms; Oxadiazoles; Protein Multimerization; Quinolines; Signal Transduction; Sorafenib; src Homology Domains; STAT3 Transcription Factor; Survivin; Xenograft Model Antitumor Assays	2020

Article

Year

Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.

Cancer science, 2020, Volume: 111, Issue:5

Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Interleukin-6; Mice; Molecular Docking Simulation; Mouth Neoplasms; Oxadiazoles; Protein Multimerization; Quinolines; Signal Transduction; Sorafenib; src Homology Domains; STAT3 Transcription Factor; Survivin; Xenograft Model Antitumor Assays

2020